Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for OCGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 100.05M
March 31, 2026 31.86M
December 31, 2025 18.57M
September 30, 2025 32.56M
June 30, 2025 27.01M
March 31, 2025 37.80M
December 31, 2024 58.51M
September 30, 2024 38.70M
June 30, 2024 15.70M
March 31, 2024 26.38M
December 31, 2023 39.46M
September 30, 2023 53.48M
June 30, 2023 70.58M
March 31, 2023 76.72M
December 31, 2022 90.93M
September 30, 2022 101.60M
June 30, 2022 115.00M
March 31, 2022 129.77M
December 31, 2021 94.96M
September 30, 2021 107.35M
June 30, 2021 115.64M
March 31, 2021 44.79M
December 31, 2020 24.04M
September 30, 2020 19.11M
June 30, 2020 14.97M
Date Value
March 31, 2020 3.193M
December 31, 2019 7.444M
September 30, 2019 15.30M
June 30, 2019 2.786M
March 31, 2019 7.376M
December 31, 2018 1.628M
September 30, 2018 5.192M
June 30, 2018 8.772M
March 31, 2018 15.51M
December 31, 2017 7.981M
September 30, 2017 12.62M
June 30, 2017 18.54M
March 31, 2017 24.37M
December 31, 2016 31.91M
September 30, 2016 37.99M
June 30, 2016 15.93M
March 31, 2016 22.90M
December 31, 2015 30.92M
September 30, 2015 37.72M
June 30, 2015 45.22M
March 31, 2015 53.18M
December 31, 2014 58.06M
September 30, 2014 3.258M
June 30, 2014 7.776M
March 31, 2014 3.36M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 956.47M
Biogen, Inc. 1.285B
Gilead Sciences, Inc. 4.882B
MannKind Corp. 111.13M
Vertex Pharmaceuticals, Inc. 7.863B